Postoperative radiotherapy in prostate cancer: Dose and volumes

被引：6
作者：
Schick, U. [1 ,2 ]
Latorzeff, I [3 ]
Sargos, P. [4 ]
机构：
[1] Univ Hosp, Radiat Oncol Dept, Brest, France
[2] Univ Brest, INSERM, LaTIM, UMR 1101, Brest, France
[3] Clin Pasteur, Dept Oncol Radiotherapy, Bat Atrium, Toulouse, France
[4] Inst Bergonie, Dept Radiotherapy, Bordeaux, France
来源：
CANCER RADIOTHERAPIE | 2021年 / 25卷 / 6-7期
关键词：
Adjuvant; Salvage; Radiotherapy; SALVAGE RADIATION-THERAPY; CLINICAL TARGET VOLUME; LYMPH-NODE VOLUMES; RADICAL PROSTATECTOMY; BED; DEFINITION; CONSENSUS; TOXICITY; TRIAL; GUIDELINES;
D O I：
10.1016/j.canrad.2021.07.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Approximately thirty percent of patients experience biochemical recurrence after radical prostatectomy for prostate cancer. Early salvage radiotherapy has recently become a standard of care in this setting. The purpose of this review is first to summarize current knowledge in terms of dose to the prostate bed in light of the recent SAKK 09/10 randomized phase III trial results. The evidence on moderate hypofractionation will also be discussed whereas extreme hypofractionation remains highly investigational. Regarding target volumes, several different guidelines have been published to address the need for standardization of postoperative target delineation. The recent GFRU (Groupe Francophone de Radiotherapie Urologique) recommendations could represent an international consensus. (C) 2021 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).
引用
收藏
页码：674 / 678
页数：5
相关论文
共 33 条
  • [1] 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
    Calais, Jeremie
    Czernin, Johannes
    Cao, Minsong
    Kishan, Amar U.
    Hegde, John V.
    Shaverdian, Narek
    Sandler, Kiri
    Chu, Fang-I
    King, Chris R.
    Steinberg, Michael L.
    Rauscher, Isabel
    Schmidt-Hegemann, Nina-Sophie
    Poeppel, Thorsten
    Hetkamp, Philipp
    Ceci, Francesco
    Herrmann, Ken
    Fendler, Wolfgang P.
    Eiber, Matthias
    Nickols, Nicholas G.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (02) : 230 - 237
  • [2] Is hypofractionation acceptable for prostate bed radiotherapy?
    Campos, Fernando Lopez
    Pardo, Gemma Sancho
    Pijoan, Xavier Maldonado
    Zilli, Thomas
    Lorenzo, Felipe Counago
    Moron, Asuncion Hervas
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (06) : 346 - 350
  • [3] Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure
    Chin, Stephen
    Fatimilehin, Abiola
    Walshaw, Richard
    Argarwal, Arjun
    Mistry, Hitesh
    Elliott, Tony
    Logue, John
    Wylie, James
    Choudhury, Ananya
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 107 (02): : 288 - 296
  • [4] Higher-than-expected Severe (Grade 3-4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients
    Cozzarini, Cesare
    Fiorino, Claudio
    Deantoni, Chiara
    Briganti, Alberto
    Fodor, Andrei
    La Macchia, Mariangela
    Chiorda, Barbara Noris
    Rancoita, Paola Maria Vittoria
    Suardi, Nazareno
    Zerbetto, Flavia
    Calandrino, Riccardo
    Montorsi, Francesco
    Di Muzio, Nadia
    [J]. EUROPEAN UROLOGY, 2014, 66 (06) : 1024 - 1030
  • [5] Proposal of a post-prostatectomy clinical target volume based on pre-operative MRI: volumetric and dosimetric comparison to the RTOG guidelines
    Croke J.
    Maclean J.
    Nyiri B.
    Li Y.
    Malone K.
    Avruch L.
    Kayser C.
    Malone S.
    [J]. Radiation Oncology, 9 (1) : 303
  • [6] PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
    De Bruycker, A.
    Spiessens, A.
    Dirix, P.
    Koutsouvelis, N.
    Semac, I.
    Liefhooghe, N.
    Gomez-Iturriaga, A.
    Everaerts, W.
    Otte, F.
    Papachristofilou, A.
    Scorsetti, M.
    Shelan, M.
    Siva, S.
    Ameye, F.
    Guckenberger, M.
    Heikkilae, R.
    Putora, P. M.
    Zapatero, A.
    Conde-Moreno, A.
    Counago, F.
    Vanhoutte, F.
    Goetghebeur, E.
    Reynders, D.
    Zilli, T.
    Ost, P.
    [J]. BMC CANCER, 2020, 20 (01)
  • [7] de Crevoisier R, 2016, Cancer Radiother, V20 Suppl, pS200, DOI 10.1016/j.canrad.2016.07.037
  • [8] Target definition in salvage postoperative radiotherapy for prostate cancer: 18F-fluorocholine PET/CT assessment of local recurrence
    El Kabbaj, Osman
    Robin, Philippe
    Bourhis, David
    Dissaux, Gurvan
    Rosenfelder, Nicola
    Valeri, Antoine
    Fournier, Georges
    Salaun, Pierre-Yves
    Pradier, Olivier
    Malhaire, Jean-Pierre
    Abgral, Ronan
    Schick, Ulrike
    [J]. ACTA ONCOLOGICA, 2018, 57 (03) : 375 - 381
  • [9] Moderate hypofractionated radiotherapy for post-operative treatment of prostate cancer: long-term outcome and pattern of toxicity
    Franzese, Ciro
    Badalamenti, Marco
    Baldaccini, Davide
    D'Agostino, Giuseppe
    Comito, Tiziana
    Franceschini, Davide
    Clerici, Elena
    Navarria, Pierina
    Reggiori, Giacomo
    Tomatis, Stefano
    Scorsetti, Marta
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (02) : 133 - 140
  • [10] Ghadjar P, 2021, TRIAL EUR UROL
1234